AUTHORS
Jia Hu, Jingyi Huang2, Xiaoqing Zou3, Yue Liang4, Yuanyuan Zhu5, Muxuan Li6, Weijia Huang7, Yi Zhao8, Weiyan Zheng, MD9, Yi Luo10, Jimin Shi11, Zhen Cai12, He Huang, MD, PhD13, Shanshan Pei, PhD14, Jie Sun, PhD15
AFFILIATIONS
1 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
2 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
3 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
4 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
5 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
6 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
7 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
8 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
9 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
10 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
11 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
12 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
13 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
14 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
15 Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
ABSTRACT
Despite the milestone clinical success of venetoclax (VEN) plus hypomethylating (VEN/HMA) agents and its combination with targeted therapies, chemotherapy remains an essential partner to VEN for achieving broad and deep remissions in many patients with acute myeloid leukemia (AML). Thus, rational design of chemotherapy regimens that address VEN resistance represents an important direction in the field. Here, we rationally designed CHA, a novel anthracycline-free regimen combining cladribine (CdA), homoharringtonine (HHT), and cytarabine (AraC) with a goal to treat VEN-resistant monocytic AML (mono-AML). We present clinical results from the CHA trial (NCT05906914), introduce an unsupervised multiparameter flow cytometry (MFC)-based approach that defines mono-AML independent of morphology and identifies patients preferentially responsive to CHA. Mechanistic analyses in primary AML samples, with validation in paired samples from CHA-treated patients, subsequently revealed that CHA targets mono-AML across its differentiation hierarchy: CdA selectively eradicates monocytic leukemia stem cells (mono-LSCs), HHT targets differentiated monocytic blasts, and AraC provides the chemotherapy backbone.
We initiated a prospective, single-center, single-arm trial in adults with newly diagnosed AML. By April 2025, 77 patients were assessed and 58 enrolled (median age 42 years; range 18–60; 55.2% female). At a median follow-up of 22.5 months (range, 0.7–37), CHA achieved an overall response rate (ORR) of 85.7% and composite complete remission (CRc) rate of 80.4%. Two-year overall survival was 90.5% (95% CI, 82.9–98.9) and disease-free survival was 76.8% (95% CI, 65.0–90.9); medians were not reached. CHA demonstrated a higher complete remission (CR) rate in mono-AML (FAB M4/M5) versus primitive AML (FAB M0/1/2) (90.6% vs 66.7%, P = 0.041).
Given the limited ability of morphology-based FAB classification to capture biological heterogeneity, unsupervised clustering based on the MFC markers classified patients into MFC-defined mono-AML, characterized by high expression of monocytic markers, and MFC-defined non-mono-AML. MFC-defined mono-AML encompassed all FAB M5 cases and achieved significantly higher rates of CRc (100% vs 71.7%; P = 0.0494) and MRD-negative CRc (100% vs 87.9%; P = 0.0142), suggesting that MFC more precisely identifies patients sensitive to CHA. We applied the same MFC clustering to two retrospective cohorts DA (daunorubicin + cytarabine) and VEN/HMA to validate its effectiveness in classifying monocytic AML. Remission rates were comparable between mono- and non-mono-AML with DA, whereas VEN/HMA-treated mono-AML had inferior outcomes, consistent with its relative VEN resistance. These findings suggest that the superior response of mono-AML to CHA reflects a regimen-specific therapeutic advantage rather than inherently favorable disease biology.
AML arises from self-renewing LSCs that drive relapse after treatment. We recently identified a developmentally distinct mono-LSCs with a CD34−/CD4+/CD11b−/CD14−/CD36− immunophenotype. Given the promising activity of CHA in mono-AML, we asked whether CHA eradicates mono-LSC compartment. Functionally validated mono-LSC-driven AML samples were treated ex vivo with vehicle, individual CHA agents, or the triplet, followed by t-distributed stochastic neighbor embedding (t-SNE), colony-forming unit assays(CFU), and xenotransplantation. CdA preferentially depleted mono-LSCs, HHT targeted mature monocytic blasts, and AraC showed no lineage preference; the triplet achieved the deepest clearance. CHA-treated specimens also lost NSG engraftment. In two patient-derived xenograft models harboring KMT2A rearrangements and KRAS mutations, CHA eliminated human CD45+ leukemia cells from bone marrow, peripheral blood, and spleen. These findings prompted us to return to the CHA cohort to make the validation. Paired diagnosis/remission single-cell RNA sequencing from an MFC-confirmed mono-AML patient showed that mono-LSCs and mature monocytic blasts dominated at baseline and were eliminated at remission.
In summary, effective treatments for mono-LSCs and mono-AML remain an unmet need in the VEN/HMA era. CHA regimen is readily applicable in the clinic and demonstrates the ability to disrupt mono-LSCs and mono-AML. In parallel, we introduce an MFC-based strategy for identifying biologically defined mono-AML, thereby linking biological classification with a clinically actionable treatment approach.
DISCLOSURES
Jie Sun, PhD: No relevant conflicts of interest to declare.